HC Wainwright Reaffirms Buy Rating for Altimmune (NASDAQ:ALT)

HC Wainwright reiterated their buy rating on shares of Altimmune (NASDAQ:ALT) in a report released on Thursday morning,Benzinga reports. They currently have a $12.00 price objective on the stock.

A number of other research firms have also weighed in on ALT. Evercore ISI upgraded shares of Altimmune to a “strong-buy” rating in a research note on Friday, August 9th. UBS Group started coverage on shares of Altimmune in a research report on Tuesday, November 12th. They issued a “buy” rating and a $26.00 price objective on the stock. Finally, B. Riley reaffirmed a “buy” rating and set a $20.00 price objective on shares of Altimmune in a research report on Monday, August 12th. Two research analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Altimmune currently has an average rating of “Moderate Buy” and an average target price of $20.00.

Altimmune Price Performance

Shares of NASDAQ:ALT opened at $7.61 on Thursday. The firm has a market capitalization of $541.22 million, a PE ratio of -4.91 and a beta of 0.09. Altimmune has a 1 year low of $2.34 and a 1 year high of $14.84. The firm’s 50-day moving average is $7.02 and its two-hundred day moving average is $6.91.

Altimmune (NASDAQ:ALT) last announced its earnings results on Tuesday, November 12th. The company reported ($0.32) earnings per share for the quarter, topping the consensus estimate of ($0.35) by $0.03. Altimmune had a negative net margin of 199,076.92% and a negative return on equity of 55.81%. The firm had revenue of $0.01 million for the quarter. During the same period in the previous year, the company earned ($0.39) earnings per share. Analysts expect that Altimmune will post -1.36 EPS for the current fiscal year.

Institutional Investors Weigh In On Altimmune

Several hedge funds and other institutional investors have recently bought and sold shares of ALT. Swiss National Bank purchased a new position in Altimmune during the 1st quarter worth approximately $1,079,000. Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Altimmune in the 1st quarter valued at $271,000. Sei Investments Co. purchased a new stake in Altimmune in the 1st quarter valued at $479,000. SG Americas Securities LLC raised its position in Altimmune by 542.8% in the 2nd quarter. SG Americas Securities LLC now owns 254,571 shares of the company’s stock valued at $1,693,000 after purchasing an additional 214,968 shares during the last quarter. Finally, Dimensional Fund Advisors LP boosted its stake in Altimmune by 142.9% during the 2nd quarter. Dimensional Fund Advisors LP now owns 570,174 shares of the company’s stock worth $3,791,000 after purchasing an additional 335,444 shares during the period. 78.05% of the stock is currently owned by institutional investors and hedge funds.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.